Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  • R. Tawil
  • J. Han
  • L. Wang
  • Vissing, John
  • B. van Engelen
  • J. Statland
  • M. Mellion
  • J. Shoskes
  • C. Morabito
  • J. Jiang
  • J. Webster
Original languageEnglish
Article numberP.136
JournalNeuromuscular Disorders
Volume32
Issue numberSupplement 1
Pages (from-to)S104-S104
Number of pages1
ISSN0960-8966
DOIs
Publication statusPublished - 2022
Event27th International Congress of the World-Muscle-Society (WMS) - Halifax, Canada
Duration: 11 Oct 2022 → 15 Oct 2022

Conference

Conference27th International Congress of the World-Muscle-Society (WMS)
CountryCanada
CityHalifax
Period11/10/2022 → 15/10/2022

ID: 345419463